Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 396.16 M
The data is delayed by 15 minutes.
ARNA is in the long-term up 181% in 4 years.
Description: Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company?s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||243.04 M||EPS||0.02||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-4.26%||Sales Growth - Q/Q||33.35%||P/E||65.5|
|P/E To EPS Growth||P/S||9.34||P/BV||3.07||Price/Cash Per Share|
|Price/Free Cash Flow||-3.59||ROA||-16.44%||ROE||-46.18%||ROI|
|Current Ratio||3.61||Quick Ratio||3.46||Long Term Debt/Equity||0.35||Debt Ratio||0.58|
|Gross Margin||76.36%||Operating Margin||-243.99%||Net Profit Margin||-140.4%||Dividend Payout Ratio|
|Cash From Financing Activities||101.41 M||Cash From Investing Activities||-1.07 M||Cash From Operating Activities||-23.02 M||Gross Profit||8.66 M|
|Net Profit||-24.3 M||Operating Profit||-21.74 M||Total Assets||362.29 M||Total Current Assets||268.62 M|
|Total Current Liabilities||74.36 M||Total Debt||70.17 M||Total Liabilities||233.35 M||Total Revenue||12.26 M|
|High 52 week||49.63||Low 52 week||30.89||Last close||43.58||Last change||-0.37%|
|RSI||72.62||Average true range||2.02||Beta||1.02||Volume||2.08 M|
|Simple moving average 20 days||7.91%||Simple moving average 50 days||9.66%||Simple moving average 200 days||6.16%|
|Performance Week||-0.91%||Performance Month||6.06%||Performance Quart||10.83%||Performance Half||-2.22%|
|Performance Year||28.63%||Performance Year-to-date||11.89%||Volatility daily||3.16%||Volatility weekly||7.07%|
|Volatility monthly||14.48%||Volatility yearly||50.18%||Relative Volume||420.94%||Average Volume||624.51 K|
|New High||New Low|
2019-09-12 11:25:03 | United Therapeutics' Trevyent NDA for PAH Accepted by FDA
2019-09-10 23:15:04 | Arena Pharmaceuticals Inc ARNA EVP, General Counsel & Sec Steven W Spector Sold $2. ...
2019-09-05 11:23:54 | Does Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA CEO Salary Compare Well With Others?
2019-08-28 08:30:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
2019-08-13 12:49:14 | 25 Biggest Marijuana Companies in the World
2019-08-08 16:47:20 | Edited Transcript of ARNA earnings conference call or presentation 7-Aug-19 8:30pm GMT
2019-08-08 16:08:47 | This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
2019-08-08 10:34:02 | Arena Pharmaceuticals' ARNA Q2 Loss Widens, Revenues Meet
2019-08-08 04:23:53 | Arena Pharmaceuticals Inc ARNA Q2 2019 Earnings Call Transcript
2019-08-06 15:50:19 | Is Arena Pharmaceuticals, Inc. NASDAQ:ARNA A High Quality Stock To Own?
2019-08-01 09:49:01 | United Therapeutics UTHR Q2 Earnings & Sales Beat, Down Y/Y
2019-07-25 09:00:01 | Arena Pharmaceuticals ARNA Upgraded to Buy: Here's Why
2019-07-09 13:32:21 | Should Arena Pharmaceuticals, Inc. NASDAQ:ARNA Be Your Next Stock Pick?
2019-06-18 12:30:04 | A Company's First Profit Can Mean Big Profits for Investors
2019-06-18 10:38:02 | Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
2019-06-14 18:29:41 | Did Hedge Funds Drop The Ball On Arena Pharmaceuticals, Inc. ARNA
2019-06-13 08:30:00 | Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19
2019-06-07 09:30:01 | Why Is Arena Pharmaceuticals ARNA Up 9.1% Since Last Earnings Report?
2019-06-06 12:32:35 | Does Market Volatility Impact Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA Share Price?
2019-05-21 07:30:00 | Corvidia Therapeutics Announces Dr. Preston Klassen Joins its Board of Directors
2019-05-13 11:35:18 | Cannabis Sector Weekly Update: Sell-Off amid Market Weakness
2019-05-13 09:00:01 | All You Need to Know About Arena Pharmaceuticals ARNA Rating Upgrade to Buy
2019-05-13 08:30:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
2019-05-10 19:45:04 | Arena Pharmaceuticals Inc ARNA Q1 2019 Earnings Call Transcript
2019-05-10 07:04:25 | Did Business Growth Power Arena Pharmaceuticals's NASDAQ:ARNA Share Price Gain of 226%?
2019-05-09 16:24:00 | S&P 500, Nasdaq end lower for fourth day after Trump claims China ‘broke the deal’
2019-05-09 16:18:50 | Edited Transcript of ARNA earnings conference call or presentation 8-May-19 8:30pm GMT
2019-05-09 09:03:01 | Arena Pharmaceuticals' ARNA Loss Widens in Q1 But Stock Up
2019-05-07 13:20:02 | Key Cannabis Sector Updates: Analyst Ratings and Earnings
2019-05-07 11:45:50 | Cannabis Stocks Had a Mixed Performance Last Week
2019-05-02 09:26:01 | United Therapeutics UTHR Down Despite Q1 Earnings Beat
2019-04-30 14:50:37 | Here’s What Hedge Funds Think About Arena Pharmaceuticals, Inc. ARNA
2019-04-29 12:05:22 | Ups and Downs in the Cannabis Space Last Week
2019-04-24 11:30:21 | The New Cannabis ETF Is Already Making Additions
2019-04-22 15:15:02 | Wall Street Ratings for Cannabis Stocks Last Week
2019-04-03 11:52:59 | What Type Of Shareholder Owns Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA?
2019-04-02 09:35:25 | Analysts Love Charlotte’s Web Holdings despite Q4 Earnings Miss
2019-03-29 09:40:13 | Charlotte’s Web Holdings Reports Record Harvest in 2018